611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Pain Management
Resources
Basic InformationLatest News
Big Rise in Hospitalized Kids With Opioid Side EffectsMost Opioid Use Concentrated in Top 10 Percent of UsersCommon Painkillers May Boost Blood Pressure in Arthritis PatientsMany Migraine Sufferers Given Unecessary Opioids, Study FindsSleep, Caffeine Use May Play Role in Post-Op PainLonger Prescriptions Make Opioid Abuse More Likely: StudyMany Prescribed Opioids Even After OverdoseReview: Cannabis May Alleviate Neuropathic PainOpioid Prescription Rates Higher in Cancer SurvivorsDoctors May Be Over-Prescribing Seizure Drugs to Treat Pain2 of 3 U.S. Patients Keep Unused Painkillers After SurgeryDoctors Still Overprescribing Opioids in U.S.Reduction of Opioid Dose May Improve Pain, Quality of LifeEasing Opioid Dose May Improve Pain and Quality of LifeAt-Risk Pain Patients Can Cut Opioid Use With Psychology ToolsHalf of Opioid Prescriptions Go to People With Mental IllnessNerve Zap Unlikely to Ease Low Back PainReaching Beyond the Prescription Pad to Treat PainRx Changes, Counseling, Regular Visits Can Cut Opioid Deaths3 Simple Steps Might Reduce Opioid OD DeathsWhen Is an Opioid Safe to Take?Patient-Controlled Analgesia Reduces Pain at Higher CostYoga Soothes Back Pain in StudyAcupuncture May Be Effective Painkiller in the ERFDA Asks Maker of Opioid Painkiller Opana ER to Pull Drug From MarketOpioids Over-Prescribed After C-Sections: StudiesPersistent Pain May Lead to Memory Troubles1 in 5 Weight-Loss Surgery Patients Using Opioids Years LaterTaking Opioids Before Knee Surgery Could Raise Pain LaterERs May Need to Rethink Opioid Prescription PracticesCommon Painkillers Tied to Slight Rise in Heart Attack RiskOpioid Use by Iraq, Afghanistan War Vets Mirrors Rest of U.S.: Study'Mindfulness' Probably Won't Cure Your Back Pain: StudyExpectations, Concerns Vary With Age for Adults at Pain ClinicMusic May Soothe the 'Savage Beast' of Post-Op PainThis Fanged Fish Might Someday Help Ease Your PainSteroid Shots Offer No Long-Term Relief for Low-Back PainInitial Rx Can Affect Likelihood of Long-Term Opioid UseOpioid Dependence Can Start in Just a Few DaysOpioid Painkillers and Xanax or Valium a Deadly Mix: StudyDiazepam Not Beneficial for Acute Low Back Pain in ERKids' OD Risk Rises When Opioids Left Out at HomeChronic Pain More Likely for Poor, Less Educated: StudySome Docs May Help Fuel Opioid Abuse EpidemicTry Drug-Free Options First for Low Back Pain, New Guidelines SayTwelve Percent of Women Fill Opioid Rx After Vaginal DeliveryLow Back Pain? Relax, Breathe and Try YogaOpioids and Alcohol a Dangerous CocktailTreatment of Hips Beneficial in Patients With Low Back PainCommon Painkillers Don't Ease Back Pain, Study Finds
Questions and AnswersLinksBook Reviews
Related Topics

Depression: Depression & Related Conditions
Medical Disorders
Mental Disorders

FDA Asks Maker of Opioid Painkiller Opana ER to Pull Drug From Market

HealthDay News
by -- Robert Preidt
Updated: Jun 9th 2017

new article illustration

FRIDAY, June 9, 2017 (HealthDay News) -- Sales of reformulated Opana ER, a prescription opioid painkiller, should be halted in the United States, the U.S. Food and Drug Administration says.

In its request Thursday for Endo Pharmaceuticals to voluntarily withdraw the drug, the FDA said the benefits of the drug may no longer outweigh the risk of abuse. It's the first time the FDA has moved to take an opioid pain medication off the market due to the public health threat of abuse.

The FDA's analysis of data gathered after the drug was approved showed that injection abuse of reformulated Opana ER (oxymorphone hydrochloride) was linked with a serious outbreak of HIV and hepatitis C, as well as cases of a serious blood disorder called thrombotic microangiopathy.

In March 2017, an FDA advisory committee concluded that the benefits of reformulated Opana ER no longer outweigh its risks.

"We are facing an opioid epidemic -- a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse," FDA Commissioner Dr. Scott Gottlieb said in an agency news release.

"We will continue to take regulatory steps when we see situations where an opioid product's risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse," he added.

Addiction to prescription opioids, which include oxycodone (Oxycontin, Percocet) and hydrocodone (Vicoprofen), is a growing epidemic in the United States. The number of opioid overdose deaths has quadrupled in the past 15 years, health officials report.

Opana ER was first approved in 2006 for the management of moderate-to-severe pain in patients who required an around-the-clock opioid for an extended period of time. In 2012, Endo replaced the original formulation of Opana ER with a new formulation intended to make the drug resistant to physical and chemical manipulation for abuse by snorting or injecting.

However, the FDA has concluded that the reformulation can't meaningfully reduce abuse of the drug.

"The abuse and manipulation of reformulated Opana ER by injection has resulted in a serious disease outbreak. When we determined that the product had dangerous unintended consequences, we made a decision to request its withdrawal from the market," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in the news release.

If Endo does not voluntarily remove reformulated Opana ER from the market, the FDA said it would withdraw approval of the drug.

Until Opana ER is taken off the market, the FDA is warning health care professionals and others of the serious risks associated with abuse of the drug.

In a statement, Endo said it's "reviewing the request and is evaluating the full range of potential options."

More information

The U.S. National Institute on Drug Abuse outlines the signs of pain medicine abuse and addiction.